Carmine, Takeda use extracellular vesicles for rare disease gene therapies

By The Science Advisory Board staff writers

June 30, 2020 -- Carmine Therapeutics has signed a research collaboration agreement with Takeda Pharmaceutical to develop gene therapies for rare diseases.

The firms will use Carmine's Regent red blood cell extracellular vesicles platform to research, develop, and commercialize nonviral gene therapies for two rare disease targets. Takeda has also committed a $5 million convertible loan to support development of the Regent platform.

In addition, Carmine will receive an upfront payment, research funding support, and potentially over $900 million in total milestone payments plus tiered royalties, the company said. Takeda has gained an option to license the programs following completion of preclinical proof-of-concept studies and would be responsible for clinical development and commercialization, according to Carmine.

Egle, Takeda collaborate on anti-Treg immunotherapies
Egle Therapeutics has formed a strategic research alliance with Takeda Pharmaceutical to validate novel regulatory T-cell (Treg) targets, against which...
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter